Navigation Links
Vion in Medical News

Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting

...AVEN, Conn., May 29 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...0, 2009. A copy of the poster will be available on vion Pharmaceuticals' website, www.vionpharm.com , o...2:00 p.m. on Saturday, May 30, 2009. About vion ...

Vion Pharmaceuticals Reports 2009 First Quarter Results

...EW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...ilable through Thursday, May 28, 2009. About vion vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)

... HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...to have an FDA decision this year." About vion Pharmaceuticals vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA

... HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) ...rst indication in the United States." About vion Pharmaceuticals vion Pharmaceuticals, Inc. is committed to extending th...

Vion Updates Conference Call Information

...hrough Thursday, November 20, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Reports 2008 Third Quarter and Nine-Month Results

...hrough Thursday, November 20, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Reports 2008 Second Quarter and Six-Month Results

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced financial results for the three-... through Thursday, August 21, 2008. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR

...nc. (OTC Bulletin Board: TPIM), RXi Pharmaceuticals Corp. (Nasdaq: RXII ), vion Pharmaceuticals Inc. (Nasdaq: vion ), Neuralstem Inc. (Amex: CUR ), Amgen Inc. (Nasdaq: AMGN ), Gilead Scien...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from the Phase III tri...presentation of the unblinded data. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals to Appeal Nasdaq Delisting

... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that it had received a letter, d...ant the Company's request for continued listing. vion Pharmaceuticals, Inc. is committed to extending th...
Vion in Medical Technology

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

...nducted at various sites in France. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

...s, Belgium, Switzerland and Norway. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from a previously cond...g/m2 of Cloretazine(R) (VNP40101M). About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that interim data from the pivot...gy Annual Meeting in December 2007. About Vion vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that data from two clinical tria...1, 2008. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co...m E354a. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced the start of an investigator-spo... as well as improve the quality of their lives." vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the U.S. Food and Drug Admi...ewers performed a comprehensive safety analysis of vion Study CLI-037. This analysis concluded that the co...(R)) in December 2007. Conference Call Details vion will hold a conference call on Tuesday, January 8,...

Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting

...FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: vion ) today announced that preliminary data from its p... poster. A copy of the poster will be available on vion Pharmaceuticals' website, http://www.vionpharm.co... be available through Monday, December 24, 2007. vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation

...ntribution in the stem cell transplant setting." vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that an investigator-sponsored t...of Clinical Oncology Annual Meeting in June 2007. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...
Vion in Biological Technology

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...W HAVEN, Conn., Feb. 17 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...d, "This NDA filing is a significant milestone for vion and for the Onrigin clinical development program. ...tions are needed for this population. About vion ...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...EW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...an Francisco from December 6-9, 2008. vion Poster Presentation The Company announc... New Trade Name for Laromustine vion will introduce Onrigin(TM) as the new trade name f...

Vion Reports 2008 First Quarter Results

... NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ -- vion PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced financial results for the three-...ained herein are provided on a post-split basis. vion Pharmaceuticals, Inc. is committed to extending th...

Vion Pharmaceuticals Files Plan With Nasdaq

...FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: vion ) today announced that it had filed a plan to achi...cision to a Nasdaq Listing Qualifications Panel. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Reports 2007 Fourth Quarter and Year-End Results

...ained herein are provided on a post-split basis. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...nce of unanticipated events. COMPANY CONTACT: vion Pharmaceuticals, Inc. Alan Kess...

Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results

...ill be available through Tuesday, April 1, 2008. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...al Cancer Institute. For additional information on vion and its product development programs, visit the Co...

Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the Company would implement...nesday, February 20, 2008. On a pre-split basis, vion Pharmaceuticals has 81,017,569 shares outstanding ...ult of the reverse stock split, every 10 shares of vion Common Stock will be combined into one share of...

Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that the Company had paid intere... interest was paid in lieu of fractional shares. vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Holds Special Meeting of Stockholders

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) announced that a Special Meeting of Stockholders... compliance with Nasdaq's listing requirements." vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics. vion has two agents in clinical trials. Cloretazine(R) ...

Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team

...FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: vion ) today announced that William Hahne, M.D. has joi...e are extremely pleased to have Bill Hahne joining vion in medical affairs. He has a wealth of experience ...ersity Affiliated Hospitals in Atlanta, Georgia. vion Pharmaceuticals, Inc. is committed to extending th...
Other Tags
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... growth during the five years to 2014 on the ... Regulations of 2010 prompted farmers to dedicate a larger ... in ethanol production. More specifically, the regulations required the ... Similarly, rapidly expanding biofuel production in the United States ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2
Other Contents